The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...
Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...
Vera Therapeutics received priority review from the FDA for its biologics license application for atacicept to treat adults ...
Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
Investing.com -- Vera Therapeutics Inc (NASDAQ:VERA) stock rose 4.4% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License ...
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing ...
FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...
The Brighterside of News on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Many patients endure hours-long infusions because antibody doses can exceed 100 milliliters, far beyond subcutaneous limits ...
Enable Injections announced today that it received a commitment from Sanofi for a $30 million investment to drive growth.
Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback